title: Subsets of CD34+ and early engraftment kinetics in allogeneic peripheral SCT for AML.
abstract: This study aimed to identify which graft product subset of CD34+ cells might be the most predictive of early hematopoietic recovery following allogeneic peripheral SCT (allo-PBSCT). The relationship between the number of 'mature' subsets of CD34+ cells (CD34+/CD33+, CD34+/CD38+, CD34+/DR+ and CD34+/CD133-) and 'immature' subsets of CD34+ cells (CD34+/CD33-, CD34+/CD38-, CD34+/DR- and CD34+/CD133+) and early neutrophil and platelet engraftment were studied in a homogeneous series (for disease, pre transplant chemotherapy, conditioning regimen and GVHD prophylaxis) of 30 AML patients after allo-PBSCT from HLA-identical siblings. In our experience, the total CD34+/CD133+ cell number was inversely correlated with the days required for the recovery of 0.5 x 10(9)/l neutrophils (r=or-0.82, P=0.02) and platelets of 20 x 10(9)/l (r=or-0.60, P=0.06); this correlation was better than the total CD34+ cell dose and neutrophil (r=or-0.70, P=0.04) and platelet engraftment (r=or-0.56, P=0.07). We suggest that a high number of CD34+/CD133+ PBSC may be associated with faster neutrophil and platelet recovery; these findings may help to predict the repopulating capacity of PBSC in patients after allo-PBSCT, especially when a relatively low number of CD34+ cells is infused.
authors.affiliation: Hematology Section, DAP, University of Bari, Bari, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Pastore
authors.forename: A
authors.initials: A
authors.lastname: Mestice
authors.forename: T
authors.initials: T
authors.lastname: Perrone
authors.forename: F
authors.initials: F
authors.lastname: Gaudio
authors.forename: M
authors.initials: M
authors.lastname: Delia
authors.forename: F
authors.initials: F
authors.lastname: Albano
authors.forename: A
authors.initials: A
authors.lastname: Russo Rossi
authors.forename: P
authors.initials: P
authors.lastname: Carluiccio
authors.forename: M
authors.initials: M
authors.lastname: Leo
authors.forename: V
authors.initials: V
authors.lastname: Liso
authors.forename: G
authors.initials: G
authors.lastname: Specchia
mesh_terms: D000071916:AC133 Antigen; D000293:Adolescent; D000328:Adult; D015703:Antigens, CD; D018952:Antigens, CD34; D002454:Cell Differentiation; D015331:Cohort Studies; D005260:Female; D006023:Glycoproteins; D006085:Graft Survival / Q000276:immunology*; D006086:Graft vs Host Disease / Q000517:prevention & control; D006650:Histocompatibility Testing; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010455:Peptides; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D012801:Sibling Relations; D013234:Stem Cells / Q000145:classification / Q000166:cytology; D014184:Transplantation, Homologous
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D018952:Antigens, CD34; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides